Ann W. Silk
About
Ann W. Silk is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Ann W. Silk has authored 89 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 23 papers in Immunology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ann W. Silk's work include Cancer Immunotherapy and Biomarkers (30 papers), CAR-T cell therapy research (29 papers) and Polyomavirus and related diseases (22 papers). Ann W. Silk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (30 papers), CAR-T cell therapy research (29 papers) and Polyomavirus and related diseases (22 papers). Ann W. Silk collaborates with scholars based in United States, Australia and Germany. Ann W. Silk's co-authors include Howard L. Kaufman, Michael P. Kane, Hasan Rehman, Christopher D. Lao, Brady T. West, M. Bassetti, Christina Tsien, Praveen K. Bommareddy, Andrew Zloza and Sharad Goyal and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Ann W. Silk
81 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ann W. Silk United States | 24 | 1.3k | 656 | 576 | 443 | 380 | 89 | 2.0k | ||
| Mateusz Opyrchal United States | 23 | 1.0k 0.8× | 406 0.6× | 694 1.2× | 328 0.7× | 327 0.9× | 101 | 1.8k | ||
| Meng-Fen Wu United States | 24 | 1.9k 1.4× | 642 1.0× | 679 1.2× | 211 0.5× | 537 1.4× | 43 | 2.6k | ||
| Paul B. Robbins United States | 30 | 1.7k 1.3× | 798 1.2× | 1.0k 1.8× | 758 1.7× | 449 1.2× | 79 | 3.1k | ||
| Cristina Puig-Saus United States | 13 | 1.4k 1.0× | 1.0k 1.5× | 704 1.2× | 247 0.6× | 238 0.6× | 18 | 2.0k | ||
| Kei Hiraoka Japan | 20 | 1.2k 0.9× | 887 1.4× | 605 1.1× | 231 0.5× | 281 0.7× | 41 | 2.1k | ||
| Cara Haymaker United States | 27 | 1.6k 1.2× | 1.4k 2.1× | 605 1.1× | 313 0.7× | 168 0.4× | 130 | 2.5k | ||
| Franz O. Smith United States | 12 | 2.1k 1.5× | 1.4k 2.1× | 491 0.9× | 282 0.6× | 326 0.9× | 20 | 2.4k | ||
| Russell K. Pachynski United States | 24 | 1.3k 1.0× | 1.4k 2.1× | 542 0.9× | 585 1.3× | 196 0.5× | 104 | 2.5k | ||
| Craig D. Peacock United States | 22 | 1.1k 0.8× | 352 0.5× | 1.2k 2.1× | 299 0.7× | 168 0.4× | 47 | 2.3k | ||
| Sofie Wilgenhof Belgium | 25 | 1.8k 1.3× | 1.4k 2.2× | 1.1k 1.9× | 391 0.9× | 196 0.5× | 86 | 2.7k |
Countries citing papers authored by Ann W. Silk
Since
Specialization
Citations
This map shows the geographic impact of Ann W. Silk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann W. Silk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann W. Silk more than expected).
Fields of papers citing papers by Ann W. Silk
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ann W. Silk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann W. Silk. The network helps show where Ann W. Silk may publish in the future.
Co-authorship network of co-authors of Ann W. Silk
This figure shows the co-authorship network connecting the top 25 collaborators of Ann W. Silk. A scholar is included among the top collaborators of Ann W. Silk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann W. Silk. Ann W. Silk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mehnert, Janice M., Sung Jae Lee, Chao‐Chin Hsu, et al.. (2025). LBA56 ECOG-ACRIN EA6174: STAMP: Surgically treated adjuvant merkel cell carcinoma with pembrolizumab, a phase III trial. Annals of Oncology. 36. S1600–S1600.
2.
Marron, Thomas U., Jason J. Luke, Brianna Hoffner, et al.. (2025). A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(3). e010760–e010760.
3.
Kim, Emily, Emily S. Ruiz, Sophia Z. Shalhout, et al.. (2024). Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 150(5). 414–414.
4.
Ladwa, Rahul, Ann W. Silk, Muhammad A. Khattak, et al.. (2024). 940TiP INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC). Annals of Oncology. 35. S652–S653.
5.
Brohl, Andrew S., Ann W. Silk, Jacob Thomas, et al.. (2024). Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 42(16_suppl). 9592–9592.
6.
Emens, Leisha A., Pedro Romero, Ana C. Anderson, et al.. (2024). Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Journal for ImmunoTherapy of Cancer. 12(6). e009063–e009063.
7.
Kim, Emily, et al.. (2024). Patterns of initial distant metastases in 151 patients undergoing surveillance for treated Merkel cell carcinoma. Journal of the European Academy of Dermatology and Venereology. 38(6). 1202–1212.
8.
Giobbie‐Hurder, Anita, Miklos C. Fogarasi, Patrick A. Ott, et al.. (2024). Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. Journal for ImmunoTherapy of Cancer. 12(8). e009061–e009061.
9.
Eddy, Kevinn, Kajal Gupta, Katie B. Freeman, et al.. (2024). Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model. JID Innovations. 4(2). 100262–100262.
10.
Liu, Kevin X., Manisha Thakuria, Jonathan D. Schoenfeld, et al.. (2024). Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence. Cancer. 130(24). 4267–4275.
11.
Hanna, Glenn J., Anita Giobbie‐Hurder, Vatche Tchekmedyian, et al.. (2024). Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. Journal of Clinical Oncology. 42(9). 1021–1030.
12.
Granger, Emily, Fadi Murad, Emily J. Anstadt, et al.. (2023). A multicenter real-world analysis of first-line systemic monotherapy for locally advanced basal cell carcinoma. JAAD Case Reports. 42. 69–71.
13.
Brohl, Andrew S., Joseph Markowitz, Zeynep Eroglu, et al.. (2023). Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9534–9534.
14.
Silk, Ann W., Brendan D. Curti, Jennifer L. Bryan, et al.. (2023). A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. Frontiers in Oncology. 13. 1108341–1108341.
15.
Granger, Emily, Emily Kim, Ann W. Silk, et al.. (2023). Definitive radiation therapy for inoperable stage III/IV cutaneous squamous cell carcinoma: A single-institution retrospective cohort study. Journal of the American Academy of Dermatology. 90(1). 187–189.
16.
Liu, Kevin X., Jonathan D. Schoenfeld, Roy B. Tishler, et al.. (2022). Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiotherapy and Oncology. 173. 32–40.
17.
Larocca, Cecilia, Nicole R. LeBoeuf, Ann W. Silk, & Howard L. Kaufman. (2020). An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. American Journal of Clinical Dermatology. 21(6). 821–832.
18.
Hanna, Glenn J., Emily S. Ruiz, Nicole R. LeBoeuf, et al.. (2020). Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). British Journal of Cancer. 123(10). 1535–1542.
19.
Margolin, Kim, Chihiro Morishima, Vamsidhar Velcheti, et al.. (2018). Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(22). 5552–5561.
20.
Jhawar, Sachin R., Praveen K. Bommareddy, Frederick J. Kohlhapp, et al.. (2017). Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. Frontiers in Oncology. 7. 202–202.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mateusz Opyrchal Breakdown of academic impact, for papers by Meng-Fen Wu Breakdown of academic impact, for papers by Paul B. Robbins Breakdown of academic impact, for papers by Cristina Puig-Saus Breakdown of academic impact, for papers by Kei Hiraoka Breakdown of academic impact, for papers by Cara Haymaker Breakdown of academic impact, for papers by Franz O. Smith Breakdown of academic impact, for papers by Russell K. Pachynski Breakdown of academic impact, for papers by Craig D. Peacock Breakdown of academic impact, for papers by Sofie Wilgenhof